Everything About AI
NextFin News - Eclat Health Solutions is weighing an initial public offering in India that could raise as much as $300 million, people familiar with the matter said, marking the second time in six weeks that a U.S.-headquartered healthcare revenue-cycle manager has turned to Indian public markets for its exit. The discussions, reported on September 15, 2026, come one week after the Herndon, Virginia-based company launched an agentic AI platform for claims recovery and three months after its founders bought the business back from Gulf Capital in a management buyout. The question the listing raises is not whether India can absorb a $300 million healthcare-services deal - it is whether Mumbai now prices American healthcare back-office work better than Wall Street does.
The Deal and the Timing
Eclat Health Solutions has held preliminary discussions with investment banks and is expected to appoint advisers soon, according to people who asked not to be identified because the talks are private. An offering could combine newly issued shares with an offer for sale of existing holdings, the people said. No size for the secondary component was disclosed, and no timeline has been set.
The sequence of events is what makes the story. On June 9, 2026, Eclat completed a management buyout from Gulf Capital, returning full ownership to its founders and management team after a five-year partnership that the company said produced a tenfold increase in revenue and profitability and built a 4,000-person global team. On September 8, it unveiled evaire Recover, a proprietary platform for accounts-receivable and denials management built on agentic AI. Founder and group CEO Karthik Polsani framed the launch as a response to a structural problem in U.S. healthcare billing:
In recent years, healthcare organizations have spent billions attempting to collect payments from insurers, burdened by rising claim denials, opaque claim statuses, and a heavy reliance on manual processes that slow cash flow and drive up the cost to collect. evaire Recover replaces these fragmented, reactive workflows with an intelligent, agentic AI platform that equips our teams to resolve complex claims faster, drive higher net collections and continually adapt as payer policies evolve.
Less than a week later, the company is exploring a public listing. For a firm that was private-equity owned until June, the speed of the pivot is notable - but the venue is the real signal.
The immediate precedent is direct and same-sector. Infinx Services, a San Jose-based healthcare revenue-cycle management company backed by KKR and Norwest Venture Partners, is separately weighing an India IPO of up to $300 million, having invited investment banks to pitch roles in a sale targeted for early next year. Two firms in the same niche, both headquartered in the United States, both serving U.S. providers and payers, both choosing India over Nasdaq within six weeks of each other, is not a coincidence. It is a sector rerating.
Why India, and why now? Three factors converged. First, Eclat already has the delivery footprint: the company operates centers across Hyderabad, Navi Mumbai, Karimnagar and Vijayawada, so an India listing aligns its capital-market home with its cost base and a large share of its workforce. Second, the Indian primary market has reopened for large transactions after a slower first half of 2026: the National Stock Exchange of India won regulatory approval in September for an offer-for-sale valued at roughly ₹30,000 crore, and a queue of more than ₹2.5 lakh crore of IPOs is waiting to clear. Third, the ownership structure is now founder-controlled, and domestic Indian investors have historically priced promoter-led narratives at a premium to sponsor-led ones.
The size puts Eclat at the top end of the Indian healthcare-services IPO market outside the hospital chains. Manipal Health Enterprises, India's largest hospital operator, received observations from the Securities and Exchange Board of India on July 3, 2026, for a public offering centered on a fresh issue of about ₹8,000 crore alongside a larger offer for sale. But Eclat is a different asset: it carries dollar-denominated revenue, offshore delivery economics, and a U.S. client base - a profile that has rarely tested Indian public markets.
The India Route Is Structural, Not a Cyclical Window
The first-order read of this news is simple: Indian equity markets are open, and a $300 million healthcare-services IPO can clear the regulator and price within months. That is true, but it is also the consensus view, and consensus is not insight. The deeper mechanism is about valuation arbitrage and control.
A U.S. revenue-cycle outsourcing firm listing on Nasdaq would be grouped with business-process outsourcers and staffing companies - a complex that trades at a discount to software and a modest premium to pure labor. In India, the same company enters a market that has been rotating domestic institutional capital into large, profitable, technology-enabled services franchises with dollar revenue and rupee costs. The spread between what Mumbai will pay and what New York would pay for the same earnings is the real driver of the listing decision, and it is wide enough to justify the friction of a cross-border listing.
This is a structural shift, not a cyclical window trade, and three pieces of evidence support that call. First, the pipeline is deep and durable: more than ₹2.5 lakh crore of offerings are queued, including mega-deals from Reliance Jio, the NSE and SBI Mutual Fund - market plumbing that will not evaporate in a single quarter. Second, the ownership model has changed durably. Gulf Capital's exit via management buyout returned control to the Polsani family, and founder-led listings in India have consistently drawn stronger debuts than sponsor-led ones because retail and domestic institutions price promoter skin-in-the-game. Third, the customer's pain is structural: initial claim-denial rates across U.S. healthcare are estimated at 12.6% in 2026, up from 11.1% in 2020, translating into roughly 806 million denied claims a year and an estimated $262 billion in rework, delayed revenue and administrative cost.
The cyclical counter-read is that the India window is simply open because global volatility has eased and the NSE's own listing has legitimized large offer-for-sale transactions. Under that view, Eclat is catching a wave that will close the next time risk appetite turns, and the listing is a timing trade rather than a regime change.
The rebuttal is in the duplication. Timing trades do not attract two direct competitors to the same venue at the same size within six weeks. When rivals independently choose the same market, they are reading the same structural signal: India offers a permanent home for dollar-revenue, offshore-cost businesses, not just a favorable quarter.
The window is open. But the door has moved.
The AI Rerating: From Headcount to Platform Multiples
The second-order question is what Eclat is actually selling to investors. Historically, revenue-cycle management was priced as labor arbitrage: low-cost coders and billers processing U.S. claims, with margins that were decent but growth that was linear in headcount, and valuation multiples to match. Eclat's September 8 launch of evaire Recover is an attempt to change that narrative - and every competitor is attempting the same thing.
The market backdrop justifies the pitch. Labor accounts for roughly 90% of claims-processing expense, which means automation that cuts manual handling flows almost directly to margin. Reworking a single denied claim costs between $25 and $181 depending on complexity, so a platform that reduces human touches per claim expands gross margin without requiring new customers. If Eclat can demonstrate in its prospectus that evaire is reducing manual handling, the multiple investors assign to its earnings expands - not because revenue grows, but because the same revenue is produced with fewer variable costs.
But "AI platform" is fast becoming the price of entry rather than a differentiator. Omega Healthcare won the 2026 Best in KLAS Award for Ambulatory RCM Services with a score of 92.2 and was named a Leader and Star Performer in Everest Group's 2026 RCM assessment, explicitly for its generative-AI and agentic-AI investments. EQT agreed to acquire GeBBS Healthcare Solutions for more than $850 million, according to people with knowledge of the deal, valuing a coding-and-RCM outsourcing firm at a level that would have been unthinkable in the headcount-arbitrage era. AGS Health, Conifer, Ensemble and R1 RCM are all pitching AI-augmented workflows.
When every vendor in a sector claims an AI platform, the press release stops being a differentiator and becomes table stakes. The real differentiator will sit in the prospectus: what percentage of claims now reach a human hand, what the denial-overturn rate is net of the AI layer, and whether gross margin expands quarter over quarter. Those are the numbers that decide whether Eclat trades at a BPO multiple or a health-technology multiple.
The Counter-Thesis: A Crowded, Possibly Mistimed Exit
The strongest case against the structural-read thesis comes from the market itself. India's IPO market slowed sharply in the first half of 2026 after a record year in 2025, when more than 100 issues raised about ₹1.75 lakh crore, and the recovery has been led by a small number of very large, household-name deals. A $300 million offshore RCM company with no India revenue base and concentrated U.S. client exposure is a harder sell than a domestic hospital chain or a consumer platform.
There is also a sequencing and valuation risk. If Infinx and Eclat both price within months of each other, the market will compare them directly. The first to list sets the comp; the second gets marked against it. If the first trades down on debut - and a meaningful share of 2026's Indian listings broke their issue price - the second faces an immediate markdown before it even opens its books. And a U.S. healthcare-services firm carries risks that Indian retail investors do not intuitively price: U.S. payer-policy changes, Medicare reimbursement shifts, and the political sensitivity of offshore handling of American medical claims.
A version of this skepticism is already circulating among investment bankers and fund managers, who have warned that the year's pipeline - estimated at more than ₹2.5 lakh crore - cannot all clear at 2025 multiples in a slower growth year. The supply of paper is the enemy of the price.
The answer to the counter-thesis is that Eclat is not trying to be a retail story. A $300 million deal with a substantial offer-for-sale component is an institutional transaction, and Indian qualified institutional buyers have shown consistent appetite for dollar-revenue franchises. But the counter-thesis names the real risk: execution and sequencing. If Eclat files after Infinx and Infinx prices poorly, Eclat's valuation gets reset before it even files.
The falsifying signal is specific and observable: if the first of the two RCM IPOs to list - Infinx, expected early next year, or Eclat - trades below its issue price for 30 consecutive trading sessions, the "structural India home for offshore RCM" thesis is wrong. It was a window, and the window has closed. Watch that 30-session mark, not the debut pop.
Who Wins, Who Is Exposed, and What to Watch
The mechanism cashes out into a clear set of beneficiaries and exposed parties. If the structural thesis holds, the winners are founder-led, dollar-revenue healthcare-services platforms with India delivery centers; the Indian investment banks and legal advisers who will capture mandates on a wave of similar listings; and domestic institutional investors seeking offshore revenue exposure without currency risk. The exposed are mid-market U.S. RCM vendors without scale or a credible AI platform, who will face better-capitalized offshore competitors post-IPO, and any sponsor holding a similar asset who now has to explain why a Mumbai exit was not chosen.
The forward look splits cleanly by time horizon:
- Short term (0-6 months): sentiment and sequencing dominate. The key events are the appointment of bookrunners - the next concrete step after "preliminary discussions" - and how the NSE's own offer-for-sale prices. A smooth NSE debut keeps the window open; a stumble narrows it.
- Medium term (6-18 months): fundamentals take over. The prospectus numbers - revenue concentration, gross margin, and the AI-driven productivity metric - will decide whether the sector rerates up or the comps compress. This is where the "platform multiple" claim gets tested.
- Long term (18 months+): structural. If two or more offshore RCM firms list successfully in India, the template is established and the remaining private-equity-backed players follow. If they stumble, the sector reverts to private sponsor-to-sponsor sales.
Scenarios, with triggers:
- Base case (55%): Eclat appoints advisers by year-end, files a draft red-herring prospectus in the first half of 2027, and prices a $250 million to $300 million deal in India alongside or shortly after Infinx. Both list and trade roughly flat to modestly positive, and the sector gains a permanent India listing route.
- Upside case (25%): The NSE and Reliance Jio deals price strongly, domestic liquidity stays deep, and Eclat's AI narrative lands with institutional investors. The deal prices at the top of the range, above $300 million, and triggers a wave of filings from offshore healthcare-services firms.
- Downside case (20%): Market volatility returns, one of the two RCM IPOs breaks issue price, and Eclat delays or pivots to a private secondary sale. The India window for offshore RCM closes for a cycle, and valuations revert to BPO multiples.
What to watch, in order: the bookrunner appointment, the SEBI filing date, the Infinx sequencing, and - most importantly - the 30-session post-listing price test on whichever RCM firm lists first.
Eclat is not just selling shares. It is placing a bet that Indian public markets will value the back office of American healthcare at a premium to American public markets - and if it is right, every private-equity-backed outsourcing firm in the country is next in line.
Explore more exclusive insights at nextfin.ai.
